scholarly journals Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Blood ◽  
2014 ◽  
Vol 123 (12) ◽  
pp. 1826-1832 ◽  
Author(s):  
Paul G. Richardson ◽  
David S. Siegel ◽  
Ravi Vij ◽  
Craig C. Hofmeister ◽  
Rachid Baz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Option ◽  
Low Dose ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Key Points ◽  
New Treatment ◽  
Randomized Phase 2

Key Points Pomalidomide plus low-dose dexamethasone significantly improved PFS vs pomalidomide alone in relapsed and refractory multiple myeloma. Pomalidomide plus low-dose dexamethasone is an important new treatment option for RRMM patients who have received multiple prior therapies.

A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS8066-TPS8066 ◽  
Author(s):  
Jesus San Miguel ◽  
Marc S. Raab ◽  
Hartmut Goldschmidt ◽  
Sagar Lonial ◽  
Paul G. Richardson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Randomized Phase 2

scholarly journals Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Blood ◽  
2017 ◽  
Vol 130 (13) ◽  
pp. 1514-1522 ◽  
Author(s):  
Elias Jabbour ◽  
Nicholas J. Short ◽  
Guillermo Montalban-Bravo ◽  
Xuelin Huang ◽  
Carlos Bueso-Ramos ◽  
...  
Keyword(s):  
Lower Risk ◽  
Low Dose ◽  
Response Rates ◽  
Hypomethylating Agents ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Key Points ◽  
Randomized Phase 2

Key Points Low-dose hypomethylating agents are safe and effective in patients with lower-risk MDS and MDS/MPN. Decitabine was associated higher response rates compared with azacitidine, especially in patients with higher-risk features.

scholarly journals Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

Blood ◽  
2016 ◽  
Vol 128 (20) ◽  
pp. 2415-2422 ◽  
Author(s):  
Shaji K. Kumar ◽  
Betsy R. LaPlant ◽  
Craig B. Reeder ◽  
Vivek Roy ◽  
Alese E. Halvorson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Adverse Events ◽  
Response Rates ◽  
Clinical Activity ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Trial ◽  
Key Points ◽  
Randomized Phase 2

Key Points The combination of ixazomib and dexamethasone has clinical activity in patients with relapsed and or refractory multiple myeloma. Higher dose of ixazomib leads to improved response rates but with higher rates of treatment related adverse events.

scholarly journals Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

Cancer ◽  
2012 ◽  
Vol 119 (2) ◽  
pp. 339-347 ◽  
Author(s):  
Darrell White ◽  
Adetola Kassim ◽  
Birbal Bhaskar ◽  
Jing Yi ◽  
Karen Wamstad ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Randomized Phase 2

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

2017 ◽  
Vol 17 (1) ◽  
pp. e131 ◽  
Author(s):  
Shaji Kumar ◽  
Norbert Grzasko ◽  
Sossana Delimpasi ◽  
Wieslaw Jędrzejczak ◽  
Sebastian Grosicki ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study

scholarly journals Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma

2018 ◽  
Vol 184 (4) ◽  
pp. 536-546 ◽  
Author(s):  
Shaji K. Kumar ◽  
Norbert Grzasko ◽  
Sosana Delimpasi ◽  
Wieslaw W. Jedrzejczak ◽  
Sebastian Grosicki ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document